{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.58","upperLimit":"0.86","value":"0.74"},{"groupId":"OG001","lowerLimit":"0.76","upperLimit":"0.97","value":"0.90"},{"groupId":"OG002","lowerLimit":"0.67","upperLimit":"0.96","value":"0.86"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"21"}],"units":"Participants"}],"description":"In patients with measurable disease after ASCT, rate of objective response after treatment. Response was assessed using the Lugano 2014 criteria.","dispersionType":"90% Confidence Interval","groups":[{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG000","title":"Diffuse Large B Cell Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG001","title":"Classical Hodgkin Lymphoma"},{"description":"Pembrolizumab 200mg IV every 3 weeks up to 8 cycles\n\nPembrolizumab: Anti-PD-1 monoclonal antibody","id":"OG002","title":"Peripheral T Cell Lymphoma"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"18 months","title":"Response Rate to Pembrolizumab","type":"SECONDARY","unitOfMeasure":"proportion of participants"}